Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Bristol Myers Squibb will spend $40 billion in the US over the next five years, CEO Christopher Boerner wrote in an opinion ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive ...

Shares of Bristol Myers Squibb Co. BMY shed 1.01% to $50.06 Monday, on what proved to be an all-around grim trading session ...

Bristol Myers Squibb Co. said it will spend $40 billion in the US over the next five years, joining a slew of drug companies ...

Board Member Dr. Karen Smith to serve as Interim Chief Medical OfficerPHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context ...

Bristol Myers Squibb CEO warns against “slashing U.S. investment in medicines or importing lackluster policies of less ...

Mohammad Mahmoud, MD, MS, reviews important updates in metastatic prostate cancer presented at AUA 2025, including promising ...

Bristol Myers Squibb plans to cut 516 jobs in NJ as part of a $2B cost-saving initiative, bringing total layoffs this year to ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

Bristol Myers Squibb (BMS) is set to cut its Lawrenceville workforce by 516 people, according to a Worker Adjustment and ...